Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SPRAVATO® (esketamine)

Medical Information

+ Save link

SPRAVATO - Suicidal Ideation and Behavior Assessment Tool (SIBAT)

Last Updated: 05/20/2024

SUMMARY

The Suicide Ideation and Behavior Assessment Tool (SIBAT) is a computerized assessment instrument that incorporates both patient and clinician-reported information relevant for suicide risk assessment. The SIBAT was developed to address limitations in existing assessment tools.
The SIBAT is currently distributed by Mapi Research Trust. To access the questionnaire or for additional information regarding conditions of use, please see link.

BACKGROUND

The SIBAT is a computerized assessment tool that was developed to assess suicide ideation and behavior.¹^-³ The SIBAT builds on existing tools including the International Suicide Prevention Trial (InterSePT) Scale for Suicidal Thinking (ISST), the Clinical Global Impression of Severity of Suicidality scale, and the ISST-Plus, which have several limitations (eg, the inability to capture changes in suicide ideation and behavior in short intervals).¹^,²

The goals of the SIBAT are to include both clinician and patient-reported information needed to assess suicide risk, differentiate measures of suicide risk prone to rapid change (eg, suicidal ideation) from those that are not (eg, history of suicidal behavior), document clinician’s assessment of imminent and long-term suicide risk along with the management plan for the patient, and meet regulatory standards for use in clinical trials.¹

The SIBAT is comprised of 8 modules (5 patient self-reported modules and 3 clinician-rated modules) that capture information on demographics, known suicide risk factors, history of suicidal behavior, and severity of suicide ideation (See Table: The Suicide Ideation and Behavior Assessment Tool Modules).¹^,²

The Suicide Ideation and Behavior Assessment Tool Modules¹^,²

Module	Title
Patient self-reported modules
Module 1	My demographic information and suicide history
Module 2	My risk/protective factors
Module 3	My current thinking
Module 4	Assessment of my suicide behavior
Module 5	Assessment of my suicide risk
Clinician-rated modules
Module 6	Clinician semi-structured interview with patient
Module 7	Clinical Global Impressions CGI-SS-R CGI-SR-I CGI-ST-LT FoST
Module 8	Judgement of optimal suicide management
Abbreviations: CGI-SR-I, Clinical Global Impression of Suicide Risk-Imminent; CGI-SS-R, Clinical Global Impression of Severity of Suicidality Revised; CGI-ST-LT, Clinical Global Impression of Suicide Risk-Long-Term; FoST, Frequency of Suicidal Thinking.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 15 April 2024.

References

Show

1	Alphs L, Canuso C, Williamson D, et al. Suicide Ideation and Behavior Assessment Tool (SIBAT): a novel measure of suicidal ideation and behavior and perceived suicide risk. Poster presented at: International Society for CNS Clinical Trials and Methodology 2015 Autumn Conference; August 27-29, 2015; Amsterdam, The Netherlands.
2	Alphs L, Williamson D, Turkoz I, et al. Validation of Suicide Ideation and Behavior Assessment Tool (SIBAT): intra- and inter-rater reliability. Poster presented at: American College of Neuropharmacology; December 9-13, 2018; Hollywood, FL.
3	Alphs L, Fu D, Canuso C. Patient and clinician acceptance of the Suicide Ideation and Behavior Assessment Tool (SIBAT). Poster presented at: Society of Biological Psychiatry (SOBP) 72nd Annual Scientific Convention; May 18-20, 2017; San Diego, CA.